Hemodynamic Therapeutics, Inc. (HTI), a portfolio company of Cato BioVentures, announces the successful completion of its initial Phase 2 clinical study of its lead compound (“HTI-101″), a patented low-dose small-molecule investigational therapy intended for patients with treatment-resistant hypertension.